Gain Operating Income from 2010 to 2025

GANX Stock

USD 2.28 0.04 1.72%

Gain Therapeutics Operating Income yearly trend continues to be fairly stable with very little volatility. Operating Income is likely to outpace its year average in 2025. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Gain Therapeutics generates from its operations. View All Fundamentals

Operating Income

First Reported

2017-12-31

Previous Quarter

-8.2 M

Current Value

-4.5 M

Quarterly Volatility

2.4 M

Covid

Check Gain Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gain Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 172.5 K, Net Interest Income of 666.2 K or Depreciation And Amortization of 100.9 K, as well as many indicators such as Price To Sales Ratio of 842, Dividend Yield of 0.0 or PTB Ratio of 3.2. Gain financial statements analysis is a perfect complement when working with Gain Therapeutics Valuation or Volatility modules.

Check out the analysis of Gain Therapeutics Correlation against competitors.

For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.

Latest Gain Therapeutics' Operating Income Growth Pattern

Below is the plot of the Operating Income of Gain Therapeutics over the last few years. Operating Income is the amount of profit realized from Gain Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Gain Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Gain Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Gain Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Gain Operating Income Regression Statistics

	Arithmetic Mean	(6,734,064)
	Geometric Mean	2,855,882
	Coefficient Of Variation	(125.18)
	Mean Deviation	7,405,035
	Median	(1,028,318)
	Standard Deviation	8,430,022
	Sample Variance	71.1T
	Range	21.2M
	R-Value	(0.84)
	Mean Square Error	23T
	R-Squared	0.70
	Significance	0.000055
	Slope	(1,479,754)
	Total Sum of Squares	1066T

Gain Operating Income History

	2025	-19 M
	2024	-20 M
	2023	-22.3 M
	2022	-17.8 M
	2021	-13.8 M
	2020	-3.5 M
	2019	-2.1 M

Other Fundumenentals of Gain Therapeutics

Non Operating Income Net Other

Gain Therapeutics Operating Income component correlations

	Net Tangible Assets	Retained Earnings	Accounts Payable	Net Receivables	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Total Liab	Net Invested Capital	Capital Stock	Net Working Capital	Short Term Debt	Long Term Debt	Short Long Term Debt	Intangible Assets	Long Term Debt Total	Capital Surpluse
Net Tangible Assets		-0.75	0.74	0.67	0.99	0.82	0.38	0.99	0.98	0.35	-0.91	0.86	0.98	0.87	0.98	0.99	-0.78	0.9	-0.31	-0.3	-0.3
Retained Earnings	-0.75		-0.88	-0.95	-0.71	-0.97	0.27	-0.74	-0.67	-0.77	0.49	-0.94	-0.68	-0.94	-0.67	-0.79	0.99	-0.94	0.65	0.61	0.61
Accounts Payable	0.74	-0.88		0.75	0.71	0.83	-0.19	0.73	0.66	0.46	-0.43	0.95	0.67	0.92	0.65	0.73	-0.87	0.86	-0.36	-0.38	-0.38
Net Receivables	0.67	-0.95	0.75		0.64	0.97	-0.25	0.67	0.6	0.9	-0.47	0.87	0.61	0.88	0.61	0.73	-0.94	0.87	-0.84	-0.78	-0.78
Total Current Assets	0.99	-0.71	0.71	0.64		0.8	0.43	1.0	0.99	0.3	-0.93	0.83	0.99	0.84	0.99	0.98	-0.75	0.87	-0.29	-0.31	-0.31
Common Stock	0.82	-0.97	0.83	0.97	0.8		-0.12	0.82	0.77	0.77	-0.61	0.93	0.77	0.93	0.77	0.86	-0.98	0.96	-0.72	-0.71	-0.71
Property Plant Equipment	0.38	0.27	-0.19	-0.25	0.43	-0.12		0.39	0.46	-0.4	-0.68	-0.06	0.46	-0.02	0.49	0.32	0.25	-0.05	0.27	0.28	0.28
Total Assets	0.99	-0.74	0.73	0.67	1.0	0.82	0.39		0.99	0.32	-0.91	0.84	1.0	0.84	0.99	0.98	-0.78	0.88	-0.33	-0.36	-0.36
Total Stockholder Equity	0.98	-0.67	0.66	0.6	0.99	0.77	0.46	0.99		0.25	-0.94	0.77	1.0	0.78	1.0	0.97	-0.71	0.83	-0.28	-0.33	-0.33
Current Deferred Revenue	0.35	-0.77	0.46	0.9	0.3	0.77	-0.4	0.32	0.25		-0.2	0.6	0.26	0.64	0.27	0.43	-0.74	0.61	-0.93	-0.79	-0.79
Net Debt	-0.91	0.49	-0.43	-0.47	-0.93	-0.61	-0.68	-0.91	-0.94	-0.2		-0.61	-0.94	-0.64	-0.95	-0.9	0.52	-0.67	0.23	0.2	0.2
Total Liab	0.86	-0.94	0.95	0.87	0.83	0.93	-0.06	0.84	0.77	0.6	-0.61		0.78	0.99	0.77	0.86	-0.94	0.95	-0.5	-0.47	-0.47
Net Invested Capital	0.98	-0.68	0.67	0.61	0.99	0.77	0.46	1.0	1.0	0.26	-0.94	0.78		0.78	1.0	0.97	-0.72	0.84	-0.28	-0.33	-0.33
Capital Stock	0.87	-0.94	0.92	0.88	0.84	0.93	-0.02	0.84	0.78	0.64	-0.64	0.99	0.78		0.78	0.88	-0.94	0.96	-0.54	-0.47	-0.47
Net Working Capital	0.98	-0.67	0.65	0.61	0.99	0.77	0.49	0.99	1.0	0.27	-0.95	0.77	1.0	0.78		0.97	-0.7	0.83	-0.29	-0.33	-0.33
Short Term Debt	0.99	-0.79	0.73	0.73	0.98	0.86	0.32	0.98	0.97	0.43	-0.9	0.86	0.97	0.88	0.97		-0.83	0.93	-0.4	-0.4	-0.4
Long Term Debt	-0.78	0.99	-0.87	-0.94	-0.75	-0.98	0.25	-0.78	-0.71	-0.74	0.52	-0.94	-0.72	-0.94	-0.7	-0.83		-0.97	0.65	0.64	0.64
Short Long Term Debt	0.9	-0.94	0.86	0.87	0.87	0.96	-0.05	0.88	0.83	0.61	-0.67	0.95	0.84	0.96	0.83	0.93	-0.97		-0.52	-0.5	-0.5
Intangible Assets	-0.31	0.65	-0.36	-0.84	-0.29	-0.72	0.27	-0.33	-0.28	-0.93	0.23	-0.5	-0.28	-0.54	-0.29	-0.4	0.65	-0.52		0.94	0.94
Long Term Debt Total	-0.3	0.61	-0.38	-0.78	-0.31	-0.71	0.28	-0.36	-0.33	-0.79	0.2	-0.47	-0.33	-0.47	-0.33	-0.4	0.64	-0.5	0.94		1.0
Capital Surpluse	-0.3	0.61	-0.38	-0.78	-0.31	-0.71	0.28	-0.36	-0.33	-0.79	0.2	-0.47	-0.33	-0.47	-0.33	-0.4	0.64	-0.5	0.94	1.0

Click cells to compare fundamentals

About Gain Therapeutics Financial Statements

Gain Therapeutics investors use historical fundamental indicators, such as Gain Therapeutics' Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Gain Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	-20 M	-19 M
Non Operating Income Net Other	-86.5 K	-90.8 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Gain Stock Analysis

When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Gain Operating Income from 2010 to 2025

Latest Gain Therapeutics' Operating Income Growth Pattern

Gain Operating Income Regression Statistics

Gain Operating Income History

Other Fundumenentals of Gain Therapeutics

Gain Therapeutics Operating Income component correlations

About Gain Therapeutics Financial Statements

Also Currently Popular

Additional Tools for Gain Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY